The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Tumor Necrosis Factor Alpha Inhibitors-Global Market Insights and Sales Trends 2025

Tumor Necrosis Factor Alpha Inhibitors-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1852164

No of Pages : 108

Ask Your Query
Synopsis
The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs.
The global Tumor Necrosis Factor Alpha Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Tumor Necrosis Factor Alpha Inhibitors in various end use industries. The expanding demands from the Medicine, Scientific Research and Others,, are propelling Tumor Necrosis Factor Alpha Inhibitors market. Humira, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Enbrel segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Tumor Necrosis Factor Alpha Inhibitors market, driven by demand from China, the second largest economy with some signs of stabilising, the Tumor Necrosis Factor Alpha Inhibitors market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Tumor Necrosis Factor Alpha Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Tumor Necrosis Factor Alpha Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Tumor Necrosis Factor Alpha Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Tumor Necrosis Factor Alpha Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Tumor Necrosis Factor Alpha Inhibitors covered in this report include GlaxoSmithKline, Sanofi, Novartis, AstraZeneca, AbbVie, LG Life Sciences, Janssen Biotech, AryoGen Pharmed and Momenta Pharmaceuticals, etc.
The global Tumor Necrosis Factor Alpha Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Sanofi
Novartis
AstraZeneca
AbbVie
LG Life Sciences
Janssen Biotech
AryoGen Pharmed
Momenta Pharmaceuticals
HanAll Biopharma
Zydus Cadila
Global Tumor Necrosis Factor Alpha Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Tumor Necrosis Factor Alpha Inhibitors market, Segment by Type:
Humira
Enbrel
Remicade
Others
Global Tumor Necrosis Factor Alpha Inhibitors market, by Application
Medicine
Scientific Research
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Tumor Necrosis Factor Alpha Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Tumor Necrosis Factor Alpha Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Tumor Necrosis Factor Alpha Inhibitors Market Overview
1.1 Tumor Necrosis Factor Alpha Inhibitors Product Overview
1.2 Tumor Necrosis Factor Alpha Inhibitors Market Segment by Type
1.2.1 Humira
1.2.2 Enbrel
1.2.3 Remicade
1.2.4 Others
1.3 Global Tumor Necrosis Factor Alpha Inhibitors Market Size by Type
1.3.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Size Overview by Type (2018-2029)
1.3.2 Global Tumor Necrosis Factor Alpha Inhibitors Historic Market Size Review by Type (2018-2023)
1.3.3 Global Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Type (2018-2023)
1.4.2 Europe Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Type (2018-2023)
2 Global Tumor Necrosis Factor Alpha Inhibitors Market Competition by Company
2.1 Global Top Players by Tumor Necrosis Factor Alpha Inhibitors Sales (2018-2023)
2.2 Global Top Players by Tumor Necrosis Factor Alpha Inhibitors Revenue (2018-2023)
2.3 Global Top Players by Tumor Necrosis Factor Alpha Inhibitors Price (2018-2023)
2.4 Global Top Manufacturers Tumor Necrosis Factor Alpha Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Tumor Necrosis Factor Alpha Inhibitors Market Competitive Situation and Trends
2.5.1 Tumor Necrosis Factor Alpha Inhibitors Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Tumor Necrosis Factor Alpha Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Alpha Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Tumor Necrosis Factor Alpha Inhibitors Market
2.8 Key Manufacturers Tumor Necrosis Factor Alpha Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Tumor Necrosis Factor Alpha Inhibitors Status and Outlook by Region
3.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Region
3.2.1 Global Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Region (2018-2023)
3.2.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Region (2018-2023)
3.2.3 Global Tumor Necrosis Factor Alpha Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Region
3.3.1 Global Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Region (2024-2029)
3.3.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Region (2024-2029)
3.3.3 Global Tumor Necrosis Factor Alpha Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Tumor Necrosis Factor Alpha Inhibitors by Application
4.1 Tumor Necrosis Factor Alpha Inhibitors Market Segment by Application
4.1.1 Medicine
4.1.2 Scientific Research
4.1.3 Others
4.2 Global Tumor Necrosis Factor Alpha Inhibitors Market Size by Application
4.2.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Size Overview by Application (2018-2029)
4.2.2 Global Tumor Necrosis Factor Alpha Inhibitors Historic Market Size Review by Application (2018-2023)
4.2.3 Global Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Application (2018-2023)
4.3.2 Europe Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales Breakdown by Application (2018-2023)
5 North America Tumor Necrosis Factor Alpha Inhibitors by Country
5.1 North America Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Country
5.1.1 North America Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2018-2023)
5.1.3 North America Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2018-2023)
5.2 North America Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Country
5.2.1 North America Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2024-2029)
5.2.2 North America Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2024-2029)
6 Europe Tumor Necrosis Factor Alpha Inhibitors by Country
6.1 Europe Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Country
6.1.1 Europe Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2018-2023)
6.1.3 Europe Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2018-2023)
6.2 Europe Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Country
6.2.1 Europe Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2024-2029)
6.2.2 Europe Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2024-2029)
7 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors by Region
7.1 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Region (2024-2029)
8 Latin America Tumor Necrosis Factor Alpha Inhibitors by Country
8.1 Latin America Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Country
8.1.1 Latin America Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2018-2023)
8.1.3 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2018-2023)
8.2 Latin America Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2024-2029)
8.2.2 Latin America Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2024-2029)
9 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors by Country
9.1 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Tumor Necrosis Factor Alpha Inhibitors Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Information
10.1.2 GlaxoSmithKline Introduction and Business Overview
10.1.3 GlaxoSmithKline Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GlaxoSmithKline Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.1.5 GlaxoSmithKline Recent Development
10.2 Sanofi
10.2.1 Sanofi Company Information
10.2.2 Sanofi Introduction and Business Overview
10.2.3 Sanofi Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Sanofi Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.2.5 Sanofi Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.3.5 Novartis Recent Development
10.4 AstraZeneca
10.4.1 AstraZeneca Company Information
10.4.2 AstraZeneca Introduction and Business Overview
10.4.3 AstraZeneca Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 AstraZeneca Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.4.5 AstraZeneca Recent Development
10.5 AbbVie
10.5.1 AbbVie Company Information
10.5.2 AbbVie Introduction and Business Overview
10.5.3 AbbVie Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AbbVie Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.5.5 AbbVie Recent Development
10.6 LG Life Sciences
10.6.1 LG Life Sciences Company Information
10.6.2 LG Life Sciences Introduction and Business Overview
10.6.3 LG Life Sciences Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 LG Life Sciences Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.6.5 LG Life Sciences Recent Development
10.7 Janssen Biotech
10.7.1 Janssen Biotech Company Information
10.7.2 Janssen Biotech Introduction and Business Overview
10.7.3 Janssen Biotech Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Janssen Biotech Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.7.5 Janssen Biotech Recent Development
10.8 AryoGen Pharmed
10.8.1 AryoGen Pharmed Company Information
10.8.2 AryoGen Pharmed Introduction and Business Overview
10.8.3 AryoGen Pharmed Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AryoGen Pharmed Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.8.5 AryoGen Pharmed Recent Development
10.9 Momenta Pharmaceuticals
10.9.1 Momenta Pharmaceuticals Company Information
10.9.2 Momenta Pharmaceuticals Introduction and Business Overview
10.9.3 Momenta Pharmaceuticals Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Momenta Pharmaceuticals Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.9.5 Momenta Pharmaceuticals Recent Development
10.10 HanAll Biopharma
10.10.1 HanAll Biopharma Company Information
10.10.2 HanAll Biopharma Introduction and Business Overview
10.10.3 HanAll Biopharma Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.10.4 HanAll Biopharma Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.10.5 HanAll Biopharma Recent Development
10.11 Zydus Cadila
10.11.1 Zydus Cadila Company Information
10.11.2 Zydus Cadila Introduction and Business Overview
10.11.3 Zydus Cadila Tumor Necrosis Factor Alpha Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Zydus Cadila Tumor Necrosis Factor Alpha Inhibitors Products Offered
10.11.5 Zydus Cadila Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Tumor Necrosis Factor Alpha Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Tumor Necrosis Factor Alpha Inhibitors Industrial Chain Analysis
11.4 Tumor Necrosis Factor Alpha Inhibitors Market Dynamics
11.4.1 Tumor Necrosis Factor Alpha Inhibitors Industry Trends
11.4.2 Tumor Necrosis Factor Alpha Inhibitors Market Drivers
11.4.3 Tumor Necrosis Factor Alpha Inhibitors Market Challenges
11.4.4 Tumor Necrosis Factor Alpha Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Tumor Necrosis Factor Alpha Inhibitors Distributors
12.3 Tumor Necrosis Factor Alpha Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock